Annual report pursuant to Section 13 and 15(d)

Subsequent Events (Details Narrative)

v3.22.1
Subsequent Events (Details Narrative)
 1 Months Ended 12 Months Ended 120 Months Ended 123 Months Ended
Mar. 10, 2022
USD ($)
shares
Mar. 02, 2022
USD ($)
Feb. 08, 2022
USD ($)
Jan. 13, 2022
USD ($)
ft²
Nov. 10, 2020
shares
Sep. 07, 2018
shares
Mar. 28, 2022
USD ($)
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
shares
Sep. 30, 2021
shares
Dec. 31, 2021
shares
Nov. 01, 2021
shares
Share based compensation expense               $ 2,450,349        
Stock Options [Member]                        
Common stock shares issuable upon exercise of rights | shares               8,000     8,000 30,000
Restricted Stock Units [Member]                        
Share based compensation expense   $ 84,300 $ 22,640                  
Options or rights, Vesting period description   These RSUs vest over 2 years, with 50% vesting on each of March 1, 2023, and March 1, 2024,                    
Common stock shares issuable upon exercise of rights | shares               8,000     8,000 30,000
Subsequent Event [Member]                        
Upfront payment             $ 10,000,000          
Pre-agreed price per test             10          
Additional milestone payment             $ 18,000,000          
Area of property | ft²       6,645                
License agreement initial term for poc             22 years          
License agreement initial term for central lab             5 years          
Share based compensation expense       $ 471,556                
Equity Distribution Agreement [Member]                        
Sale of stock number shares issued | shares         754,348 2,539,606   308,609 2,227,797 396,448 190,600  
Equity Distribution Agreement [Member] | Subsequent Event [Member]                        
Sale of stock number shares issued | shares 3,000                      
Proceed from sale of stock $ 9,468